Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that aggressive marketing campaigns coupled with emerging agents' more manageable side effects will increase diagnosis rates and the use of pharmacologic prophylaxis for migraine in the major pharmaceutical markets (United States, France, Germany, Spain, Italy, Japan, and the United Kingdom) in the next ten years.

"We estimate that approximately 40% of migraine sufferers in the United States were diagnosed with the condition in 2003; in 2013, nearly half of U.S. migraineurs will be diagnosed with the condition," said Kate Hohenberg, therapeutic area director at Decision Resources. "This expectation is in line with the documented increases in consultation and diagnosis that have occurred in the past ten years."

The new Pharmacor study entitled Migraine Prophylaxis also finds that the niche market for menstrual migraine prevention will enable several companies to garner attractive extensions to their in-line products. For example, Vernalis and GlaxoSmithKline, the manufacturers of frovatriptan and naratriptan, respectively, are conducting trials of their 5HT1 agonists in support of labeling for prevention of menstrually associated migraine.

Side Effects of Migraine

Currently available prophylactic agents are associated with several bothersome side effects, including weight gain - a particularly thorny issue for female patients, who make up 80% of the migraine population. Other common side effects include dizziness, somnolence, and undesirable cognitive effects (e.g., slowed thinking), any one of which can prompt a patient to discontinue treatment.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Crohn's Disease Drug Market to Experience Dynamic Growth of 73% by 2013

View Now